​
​

Centessa Pharmaceuticals (CNTA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CNTA Stock Forecast

Centessa Pharmaceuticals stock forecast is as follows: an average price target of $23.25 (represents a 38.89% upside from CNTA’s last price of $16.74) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

CNTA Price Target

The average price target for Centessa Pharmaceuticals (CNTA) is $23.25 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $19.00. This represents a potential 38.89% upside from CNTA's last price of $16.74.

CNTA Analyst Ratings

Buy

According to 8 Wall Street analysts, Centessa Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CNTA stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Centessa Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024Debjit ChattopadhyayGuggenheim$28.00$17.1063.74%67.26%
Sep 19, 2024Jeffrey HungMorgan Stanley$26.00$15.8564.04%55.32%
Sep 11, 2024Kelly ShiJefferies$19.00$14.9926.75%13.50%
Sep 10, 2024Kostas BiliourisBMO Capital$20.00$16.0224.84%19.47%
Aug 14, 2024Kostas BiliourisBMO Capital$15.00$12.6019.05%-10.39%
Row per page
Go to

The latest Centessa Pharmaceuticals stock forecast, released on Nov 15, 2024 by Debjit Chattopadhyay from Guggenheim, set a price target of $28.00, which represents a 63.74% increase from the stock price at the time of the forecast ($17.10), and a 67.26% increase from CNTA last price ($16.74).

Centessa Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts145
Avg Price Target$28.00$23.25$21.60
Last Closing Price$16.74$16.74$16.74
Upside/Downside67.26%38.89%29.03%

In the current month, the average price target of Centessa Pharmaceuticals stock is $28.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 67.26% increase as opposed to Centessa Pharmaceuticals's last price of $16.74. This month's average price target is up 20.43% compared to last quarter, and up 29.63% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 19, 2024Morgan StanleyEqual-WeightOverweightUpgrade
Sep 18, 2024B. Riley-BuyInitialise
Sep 11, 2024JefferiesBuyBuyHold
Sep 11, 2024GuggenheimBuyBuyHold
Sep 09, 2024BMO CapitalOutperformOutperformHold
Aug 14, 2024BMO CapitalOutperformOutperformHold
Jul 18, 2024Oppenheimer-OutperformInitialise
Jun 21, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Aug 12, 2022Morgan StanleyOverweightUnderweightDowngrade
Aug 12, 2022Morgan Stanley-OverweightDowngrade
Row per page
Go to

Centessa Pharmaceuticals's last stock rating was published by Morgan Stanley on Sep 19, 2024. The company Upgrade its CNTA rating from "Equal-Weight" to "Overweight".

Centessa Pharmaceuticals Financial Forecast

Centessa Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Centessa Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CNTA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Centessa Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict CNTA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Centessa Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Centessa Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-49.21M$-49.70M$-47.37M$-44.47M$-49.41M$-46.07M$-42.39M
High Forecast$-49.21M$-49.70M$-47.37M$-40.96M$-37.59M$-46.07M$-42.39M
Low Forecast$-49.21M$-49.70M$-47.37M$-49.15M$-76.26M$-46.07M$-42.39M
Surprise %-------

Centessa Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CNTA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Centessa Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Centessa Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CNTA last annual SG&A of $NaN (undefined).

Centessa Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.42$-0.43$-0.41$-0.38$-0.42$-0.40$-0.39
High Forecast$-0.42$-0.43$-0.41$-0.35$-0.32$-0.40$-0.39
Low Forecast$-0.42$-0.43$-0.41$-0.42$-0.66$-0.40$-0.39
Surprise %-------

According to undefined Wall Street analysts, Centessa Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CNTA previous annual EPS of $NaN (undefined).

Centessa Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HLVXHilleVax$1.79$32.001687.71%Hold
IPSCCentury Therapeutics$1.26$15.001090.48%Buy
OPTOpthea$3.28$14.00326.83%Buy
STROSutro Biopharma$2.67$11.14317.23%Buy
LRMRLarimar Therapeutics$6.08$20.33234.38%Buy
CCCCC4 Therapeutics$4.05$13.50233.33%Buy
GNFTGenfit$4.31$13.00201.62%Buy
CGEMCullinan Oncology$12.58$31.50150.40%Buy
ERASErasca$2.64$6.50146.21%Buy
MLYSMineralys Therapeutics$12.60$30.00138.10%Buy
DSGNDesign Therapeutics$5.48$9.6776.46%Buy
EWTXEdgewise Therapeutics$31.95$45.0040.85%Buy
CNTACentessa Pharmaceuticals$16.74$23.2538.89%Buy
TARSTarsus Pharmaceuticals$46.58$62.0033.10%Buy
CRNXCrinetics Pharmaceuticals$56.07$70.1425.09%Buy
NUVLNuvalent$91.17$111.5722.38%Buy
IRONDisc Medicine$62.55$72.5015.91%Buy
TRDAEntrada Therapeutics$17.93$20.0011.54%Buy
GRCLGracell Bio$10.25$6.00-41.46%Buy

CNTA Forecast FAQ

Is Centessa Pharmaceuticals a good buy?

Yes, according to 8 Wall Street analysts, Centessa Pharmaceuticals (CNTA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of CNTA's total ratings.

What is CNTA's price target?

Centessa Pharmaceuticals (CNTA) average price target is $23.25 with a range of $19 to $28, implying a 38.89% from its last price of $16.74. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Centessa Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for CNTA stock, the company can go up by 38.89% (from the last price of $16.74 to the average price target of $23.25), up by 67.26% based on the highest stock price target, and up by 13.50% based on the lowest stock price target.

Can Centessa Pharmaceuticals stock reach $30?

CNTA's average twelve months analyst stock price target of $23.25 does not support the claim that Centessa Pharmaceuticals can reach $30 in the near future.

What is Centessa Pharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $28 price target for Centessa Pharmaceuticals (CNTA) this month, up 67.26% from its last price of $16.74. Compared to the last 3 and 12 months, the average price target increased by 38.89% and increased by 29.03%, respectively.

What are Centessa Pharmaceuticals's analysts' financial forecasts?

Centessa Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-138M (high $-126M, low $-165M), average SG&A $0 (high $0, low $0), and average EPS is $-1.208 (high $-1.107, low $-1.439). CNTA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-191M (high $-187M, low $-195M), average SG&A $0 (high $0, low $0), and average EPS is $-1.641 (high $-1.611, low $-1.681).